POLLUTION FILE

FROM (NAME & LOCATION) Rubber & Process Chemicals Division - P. R. Graham

DATE : April 14, 1972

SUBJECT : MCA Committee on Phthalates

REFERENCE :

TO : File

cc: R. W. Bucknell B3NB
M. W. Farrar R2E
R. E. Kelly A2SA
J. E. Springgate B3NA
E. P. Wheeler A2SA
xf: Baxter Travenol

The following items were discussed with Robert Gesler at Baxter-Travenol Labs relative to the phthalate project.

1. The completion of the joint study (Baxter, McGaw, Cutter, Abbott) on phthalates in biomedical applications will not be completed for several months. These data will be made available to the MCA group for effective publication.

2. Meanwhile, Baxter will prepare statements relating to the necessity of using PVC for the blood and intravenous administration bags and the risk vs. benefit ramification relating to these uses. Hopefully, this paper will be ready for the April 27 meeting in Washington.

3. Baxter has found a wide range of toxicological effects from ten samples of commercial DOP. The results range from an extremely low order of acute oral toxicity with medical grade (distilled) DOP to a relatively high order of toxicity with some commercial DOP. This gives further credence to the possibility of impurities in DOP being the cause for noted untoward effects. One sample contained "as much as 10-20% phthalic anhydride." Gesler questioned as to the inclusion of the washing step in all of these processes.

DRG

P. R. Graham

/jar

DSW 588230

REV. 11-68

STLCOPCB4093566